Keel Infrastructure Corp. Common Stock vs Novavax Inc — how do they compare? Keel Infrastructure Corp. Common Stock trades at $3.08 (market cap $1.93B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Keel Infrastructure Corp. Common Stock and Novavax Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 1 Days and Novavax Inc for 59 Days on average.
| KEEL | NVAX | |
|---|---|---|
Market Cap | $1.93B | $1.82B |
Volume | 30,868,523 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $6.66 | $12.56 |
52-Week Low | $1.71 | $6.22 |
Typical Hold Time | 1 Days | 59 Days |
Enterprise Value | $2.25B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →